None

None

None

None

None

1 march 4  

This is a randomized, open-label, parallel group study to determine the optimal dose of CART-19 cells (of the two dose levels being assessed (1-5x10xE8 vs. 1-5x10xE7 CART-19 cells). This trial will be conducted in two stages. In Stage 2, the selected dose cohort will be expanded to enroll additional subjects, …

2 march edit9  

This is a randomized, open-label, parallel group study to determine the optimal dose of CART-19 cells (of the two dose levels being assessed (1-5x10xE8 vs. 1-5x10xE7 CART-19 cells). This trial will be conducted in two stages. In Stage 2, the selected dose cohort will be expanded to enroll additional subjects, …

Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen

Some researchers have taken T cells from a person's blood, grown more of them in the laboratory and then given them back to the person. The antibody used in this study targets CLL-1. This antibody sticks to AML cells because of a substance (protein) on the outside of these cells …

Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies

This is a study to evaluate the safety and clinical activity of ThisCART19 (Allogeneic CAR-T targeting CD19) in patients with refractory or relapsed CD19 positive B cell malignancies.

Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

This is a single arm study to evaluate the efficacy and safety of CD19-targeted CAR-T cells therapy for patients with relapsed/refractory CD19+ B Cell Leukemia and Lymphoma.